As the leader in in vitro diagnostics (IVD), we discover and develop novel, high-quality, accurate assays for heart failure diagnostics, through:
The burden of cardiovascular diseases is substantial and expected to increase in coming years.13-17 Heart failure alone carries a significant burden.16 More than 64 million people are living with heart failure.16 30% of patients are readmitted, 15% die in the 60–90 days following discharge after acute heart failure, and 50% of them will die within 5 years of the moment they got admitted to the hospital18,44-47
Economic impacts are also severe, with the global economic burden of heart failure estimated at $346 billion USD (expected to increase 127% by 2030). This includes direct medical costs as well as indirect costs related to loss of productivity and caregiving needs.19,20 Imagine the impact that accurate and timely diagnosis of heart failure could have on this huge disease burden. At Roche, we have been working to reduce this burden for over 20 years.2,21-25
Our work has led to extensive clinical validation, including rule-in-rule-out processes in diverse populations, and has informed major clinical guidelines.27,28
Diagnosis of acute or chronic heart failure is commonly missed or delayed by years.29-32 The symptoms of heart failure are not specific, which often leads to misdiagnosis.33,34 Early recognition of the risk to develop heart failure with cardiac biomarker NT-proBNP and timely initiation of appropriate treatment can help reduce morbidity and mortality.24
Roche is committed to reducing the burden of heart failure. Especially in patients with type 2 diabetes mellitus, who are more likely to die from cardiovascular diseases than the general population.35
We are working extensively with patient communities, clinical societies and policy makers to combat underdiagnosis and late diagnosis of heart failure patients. For example, the ‘Peptide for Life’ initiative can help to overcome barriers to natriuretic peptide use in the emergency department.36-38
As the pioneer of NT-proBNP, we at Roche support clinical decision-making at every stage of care in heart failure,1-5 with assays that can help provide diagnostic confidence.4,5 We have a history of over 20 years of NT-proBNP evidence generation, with our NT-proBNP assay featured in more than 1,100 peer-reviewed publications, and clinically validated results integrated into clinical practice and guidelines.12,39-42
Serial measurements of NT-proBNP are a strong predictor of outcomes in heart failure supporting routine NT-proBNP monitoring to assist in clinical decision-making,39 aiding in risk stratification, prognosis during hospitalization and post-discharge prognosis.43
We have a history of over 20 years of NT-proBNP evidence generation, with our NT-proBNP assay featured in more than 1,100 peer-reviewed publications, and clinically validated results integrated into clinical practice and guidelines.12,39-42
Our validated cobas® h 232 and Elecsys® NT-proBNP offering is standardized across the Point of Care (PoC) and the central laboratory, enabling consistent management wherever care is given, potentially without re-baselining patients' levels.44
References:
